ArticleAngiogenesis2014

Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.

William Cruz-Muñoz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.